Biotech | October 07, 2025
PromoCell launches custom GMP cell culture media to power next-gen cell and gene therapies
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Findings likely to generate hypotheses about potential new uses of drugs
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Swiftmelt 1515-I meets performance requirements and secures skin attachment
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Subscribe To Our Newsletter & Stay Updated
